Dr. Mogelsvang has served as our President, Chief Executive Officer, and a member of our Board of Directors since June, 2017. He is a biotechnology executive and entrepreneur with over 25 years of industry experience. Prior to joining the Company, Dr. Mogelsvang was the President and Chief Executive Officer of Peak Pharmaceuticals, where he led the Company from its inception to a profitable veterinary health business. He also co-founded Serpin Pharma, a clinical-stage biotechnology company, serving as Vice President of Research and Development, and Caerus Discovery, an immunology-focused biotechnology company supported by BioWa – Kyowa Hakko Kirin and ImmunoCellular Therapeutics, where he served as Head of Research and Development. Additionally, he is the founder of Exxel Pharma and has been involved in multiple other biotechnology ventures.

Dr. Mogelsvang holds a Ph.D. in Biochemistry from the University of Cambridge and an M.Sc. in Plant Molecular Biology from the University of Copenhagen.

Dr. Piomelli has served as our Chief Scientific Officer since May, 2018. He has an extensive background in neuroscience research and drug discovery, with a career spanning over three decades.

Dr. Piomelli earned his Ph.D. in Neuroscience from Columbia University College of Physicians and Surgeons (1983–1988), where he trained under James H. Schwartz and Nobel Laureate Eric R. Kandel. He subsequently completed postdoctoral research at The Rockefeller University (1988–1990) under Nobel Laureate Paul Greengard. He then held research positions at INSERM in Paris (1990–1995) and The Neurosciences Institute in La Jolla (1995–1998), where he worked with Nobel Laureate Gerald Edelman.

Since 1998, Dr. Piomelli has been a faculty member at the University of California, Irvine, School of Medicine, where he currently holds the Louise Turner Arnold Chair in Neurosciences and serves as Distinguished Professor of Anatomy and Neurobiology, Pharmacology, and Biological Chemistry.

Dr. Piomelli is also a scientific co-founder of several biotechnology companies, including Kadmus Pharmaceuticals, Thesan Pharmaceuticals, and NeoKera.

Mr. Dickey has more than 25 years of experience in C-suite financial leadership for life science and medical device companies, both private and public, ranging from preclinical development to commercial operations and across a variety of disease areas and medical technologies.

Mr. Dickey has served as Managing Director at Foresite Advisors since March 2020 assuming responsibility for CFO advisory, financial analysis, capital raising, and transactional support/execution for public offerings and M&A services at life science companies. Mr. Dickey serves as a member on the Board of Directors of AngioGenex, SFA Therapeutics and GSNO Therapeutics.  Throughout his career he has demonstrated C-level (CFO, COO and CEO) and Board level experience in public, private, revenue stage and development stage life sciences and medical device companies and has played a leading role in two start-ups.

Earlier in his career, Mr. Dickey spent 18 years in investment banking, primarily at Lehman Brothers, with a background split between mergers and acquisitions and capital markets transactions. Mr. Dickey is experienced in all stages of the business lifecycle, including start-up, high-growth and turnarounds, and in building businesses and achieving an exit. He also has international experience, expertise in public and private financings, M&A, partnering/licensing transactions, project management and Chapter 11 reorganizations, as well as interacting with boards, VC’s, shareholders and Wall Street.

Mr. Dickey has an MBA from The Wharton School and an AB from Princeton University.

Dr. Paul has served as our Chief Medical Officer since November, 2024 and from 2018 to 2023. He is a licensed physician with over 20 years of experience in drug development, regulatory affairs, and clinical research.

Dr. Paul completed his postgraduate training at Albert Einstein College of Medicine, followed by an Internal Medicine Residency at Rutgers University and a Fellowship in Endocrinology at Harvard Medical School/Joslin Diabetes Center.

After nine years in clinical practice, Dr. Paul transitioned into pharmaceutical research, initially joining Pfizer. He subsequently held executive leadership positions in clinical research, regulatory affairs, and medical safety at Ergo Science, Grünenthal USA, Shionogi USA, and Schering-Plough Corporation. Notably, he was the founding Managing Director of Grünenthal USA, where he established the U.S. subsidiary for Grünenthal GmbH of Germany.

Dr. Paul has extensive experience in medical safety, clinical research, and regulatory strategy. He has worked across multiple divisions of the U.S. Food and Drug Administration (FDA), supporting numerous Investigational New Drug (IND) and New Drug Applications (NDA) with the FDA and other international regulatory agencies.